Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company focused on developing innovative cancer therapies, has announced the granting of inducement awards under its 2023 Inducement Plan. On October 1, 2024, the company granted stock options to five new employees, allowing them to purchase up to 62,700 shares of common stock.
The stock options have a four-year vesting schedule. Specifically, 25% of the underlying shares will vest on the one-year anniversary of the vesting commencement date. Following that, 1/48th of the underlying shares will vest monthly over the next 36 months. These vesting terms are subject to the employee's continued service relationship with Syndax throughout the applicable vesting dates.
Syndax Pharmaceuticals (Nasdaq: SNDX), un'azienda biopharmaceuticale in fase commerciale, focalizzata sullo sviluppo di terapie innovative per il cancro, ha annunciato l'assegnazione di premi di induzione nell'ambito del suo Piano di Induzione 2023. Il 1 ottobre 2024, l'azienda ha concesso opzioni su azioni a cinque nuovi dipendenti, consentendo loro di acquistare fino a 62.700 azioni ordinarie.
Le opzioni su azioni hanno un programma di maturazione di quattro anni. In particolare, il 25% delle azioni sottostanti sarà maturato al primo anniversario della data di inizio della maturazione. Dopo di che, 1/48 delle azioni sottostanti maturerà mensilmente nei successivi 36 mesi. Questi termini di maturazione sono soggetti al continuo rapporto di servizio del dipendente con Syndax durante le date di maturazione applicabili.
Syndax Pharmaceuticals (Nasdaq: SNDX), una empresa biofarmacéutica en etapa comercial, centrada en desarrollar terapias innovadoras contra el cáncer, ha anunciado la concesión de premios de inducimiento bajo su Plan de Inducimiento 2023. El 1 de octubre de 2024, la compañía otorgó opciones sobre acciones a cinco nuevos empleados, permitiéndoles comprar hasta 62,700 acciones comunes.
Las opciones sobre acciones tienen un programa de adquisición de cuatro años. Específicamente, el 25% de las acciones subyacentes se adquirirán en el primer aniversario de la fecha de inicio de adquisición. A partir de ahí, 1/48 de las acciones subyacentes se adquirirán mensualmente durante los siguientes 36 meses. Estos términos de adquisición están sujetos a la relación de servicio continua del empleado con Syndax durante las fechas de adquisición aplicables.
Syndax Pharmaceuticals (Nasdaq: SNDX)는 혁신적인 암 치료법 개발에 집중하는 상업 단계의 생명공학 회사로, 2023 유인 계획에 따라 유인 보상을 제공했다고 발표했습니다. 2024년 10월 1일, 회사는 다섯 명의 신규 직원에게 주식 옵션을 부여하여 최대 62,700 주의 보통주를 구매할 수 있도록 했습니다.
이 주식 옵션은 4년의 근속 일정을 가지고 있습니다. 구체적으로 말하면, 기초 주식의 25%는 근속 시작일의 1주년 기념일에 따라 근속할 것입니다. 그 후, 기초 주식의 1/48이 다음 36개월 동안 매달 근속됩니다. 이러한 근속 조건은 해당 근속 날짜 동안 Syndax와의 지속적인 서비스 관계에 따라 달라질 수 있습니다.
Syndax Pharmaceuticals (Nasdaq: SNDX), une entreprise biopharmaceutique en phase commerciale axée sur le développement de thérapies innovantes contre le cancer, a annoncé l'octroi de primes d'incitation dans le cadre de son Plan d'Incitation 2023. Le 1er octobre 2024, l'entreprise a accordé des options d'achat d'actions à Cinq nouveaux employés, leur permettant d'acheter jusqu'à 62 700 actions ordinaires.
Les options d'achat d'actions ont un calendrier de vesting de quatre ans. Plus précisément, 25 % des actions sous-jacentes pourront être exercées lors du premier anniversaire de la date de début du vesting. Par la suite, 1/48 des actions sous-jacentes seront acquises mensuellement pendant les 36 mois suivants. Ces conditions de vesting sont soumises à la continuité de la relation de service de l'employé avec Syndax tout au long des dates de vesting applicables.
Syndax Pharmaceuticals (Nasdaq: SNDX), ein biopharmazeutisches Unternehmen in der Vermarktungsphase, das sich auf die Entwicklung innovativer Krebstherapien konzentriert, hat die Vergabe von Anreizprämien im Rahmen seines Anreizplans 2023 bekannt gegeben. Am 1. Oktober 2024 gewährte das Unternehmen fünf neuen Mitarbeitern Aktienoptionen, die es ihnen ermöglichen, bis zu 62.700 Aktien zu erwerben.
Die Aktienoptionen haben einen Vesting-Zeitrahmen von vier Jahren. Genauer gesagt, 25 % der zugrunde liegenden Aktien verfallen am ersten Jahrestag des Beginns des Vestings. Danach verfallen 1/48 der zugrunde liegenden Aktien monatlich über die nächsten 36 Monate. Diese Vesting-Bedingungen hängen von der kontinuierlichen Dienstbeziehung des Mitarbeiters mit Syndax während der jeweiligen Vesting-Daten ab.
- Granted stock options to attract and retain new talent
- Implemented a long-term vesting schedule to encourage employee retention
- Potential dilution of existing shareholders' stock value
About Syndax
Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment for both revumenib and Niktimvo. For more information, please visit www.syndax.com/ or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
View original content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302266863.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
How many new employees received stock options from Syndax Pharmaceuticals (SNDX) on October 1, 2024?
What is the vesting schedule for the stock options granted by Syndax Pharmaceuticals (SNDX)?
How many shares of common stock can be purchased through the inducement awards granted by Syndax Pharmaceuticals (SNDX)?
Under which plan did Syndax Pharmaceuticals (SNDX) grant the inducement awards?
